PL3788040T3 - Pirydazynony jako inhibitory parp7 - Google Patents

Pirydazynony jako inhibitory parp7

Info

Publication number
PL3788040T3
PL3788040T3 PL19723272.1T PL19723272T PL3788040T3 PL 3788040 T3 PL3788040 T3 PL 3788040T3 PL 19723272 T PL19723272 T PL 19723272T PL 3788040 T3 PL3788040 T3 PL 3788040T3
Authority
PL
Poland
Prior art keywords
pyridazinones
parp
Prior art date
Application number
PL19723272.1T
Other languages
English (en)
Polish (pl)
Inventor
Melissa Marie Vasbinder
Laurie B. Schenkel
Kerren Kalai Swinger
Kevin Wayne Kuntz
Original Assignee
Ribon Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc. filed Critical Ribon Therapeutics Inc.
Publication of PL3788040T3 publication Critical patent/PL3788040T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19723272.1T 2018-04-30 2019-04-29 Pirydazynony jako inhibitory parp7 PL3788040T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664544P 2018-04-30 2018-04-30
PCT/US2019/029582 WO2019212937A1 (en) 2018-04-30 2019-04-29 Pyridazinones as parp7 inhibitors

Publications (1)

Publication Number Publication Date
PL3788040T3 true PL3788040T3 (pl) 2023-08-07

Family

ID=66476851

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19723272.1T PL3788040T3 (pl) 2018-04-30 2019-04-29 Pirydazynony jako inhibitory parp7

Country Status (36)

Country Link
US (6) US10550105B2 (enExample)
EP (2) EP4234551A3 (enExample)
JP (2) JP6942896B2 (enExample)
KR (1) KR102862474B1 (enExample)
CN (2) CN112424188B (enExample)
AR (1) AR121419A1 (enExample)
AU (2) AU2019262927B2 (enExample)
BR (1) BR112020022006A2 (enExample)
CA (1) CA3098585A1 (enExample)
CL (1) CL2020002821A1 (enExample)
CO (1) CO2020013599A2 (enExample)
CR (1) CR20200518A (enExample)
CY (1) CY1126132T1 (enExample)
DK (1) DK3788040T3 (enExample)
EA (1) EA202092590A1 (enExample)
EC (1) ECSP20069404A (enExample)
ES (1) ES2949538T3 (enExample)
FI (1) FI3788040T3 (enExample)
HR (1) HRP20230458T1 (enExample)
HU (1) HUE062096T2 (enExample)
IL (2) IL308983B2 (enExample)
LT (1) LT3788040T (enExample)
MA (1) MA52486B1 (enExample)
MD (1) MD3788040T2 (enExample)
MX (2) MX2020011465A (enExample)
PE (1) PE20211382A1 (enExample)
PH (1) PH12020551760A1 (enExample)
PL (1) PL3788040T3 (enExample)
PT (1) PT3788040T (enExample)
RS (1) RS64283B1 (enExample)
SG (1) SG11202010183XA (enExample)
SI (1) SI3788040T1 (enExample)
SM (1) SMT202300172T1 (enExample)
TW (2) TWI877697B (enExample)
WO (1) WO2019212937A1 (enExample)
ZA (1) ZA202006549B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
TWI877697B (zh) 2018-04-30 2025-03-21 美商律幫治療股份有限公司 作為parp7抑制劑的嗒酮
US11512090B2 (en) 2018-06-11 2022-11-29 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
WO2020051153A1 (en) 2018-09-04 2020-03-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine m1 receptor antagonists
EP3941475A4 (en) * 2019-03-20 2023-01-25 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE THEREOF
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
BR112022006686A2 (pt) * 2019-10-07 2022-10-11 Pipeline Therapeutics Inc Antagonistas de receptor muscarínico de acetilcolina m1
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
US11691969B2 (en) 2019-10-30 2023-07-04 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibtors
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
AU2021261383A1 (en) * 2020-04-23 2022-11-17 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
CA3186684A1 (en) * 2020-06-09 2021-12-16 Relive Therapeutics Inc. Compounds comprising a three ring core as pd-1/pd-l1 blockers
EP4174069A4 (en) * 2020-07-03 2024-07-10 Wuhan LL Science and Technology Development Co., Ltd. HETEROCYCLIC COMPOUND AND ASSOCIATED USE
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达（四川）生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
JP7623826B2 (ja) * 2020-12-18 2025-01-29 株式会社 資生堂 Ｔｉｐａｒｐ産生促進剤
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
EP4289845A4 (en) * 2021-02-03 2025-01-08 Shanghai Apeiron Therapeutics Company Limited Triheterocyclic compound, preparation method therefor, and application thereof
US20240317755A1 (en) * 2021-02-07 2024-09-26 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound, and intermediate thereof, preparation method therefor and use thereof
JP2024506612A (ja) * 2021-02-09 2024-02-14 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｐａｒｐ７阻害剤として有用な三環式誘導体
TW202245777A (zh) * 2021-02-16 2022-12-01 美商律幫治療股份有限公司 Parp7抑制劑之給藥方案
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
CN117425648A (zh) * 2021-03-12 2024-01-19 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
AU2022239403A1 (en) * 2021-03-16 2023-09-21 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Nitrogen-containing heterocyclic polycyclic compound, preparation method therefor, and application thereof
IL305956A (en) 2021-03-31 2023-11-01 Duke Street Bio Ltd Pharmaceutical material
GB202114315D0 (en) * 2021-10-06 2021-11-17 Duke Street Bio Ltd Pharmaceutical compound
TW202302602A (zh) * 2021-04-23 2023-01-16 大陸商四川海思科製藥有限公司 並環雜環衍生物及其在醫藥上的應用
MX2023013840A (es) * 2021-05-21 2023-12-08 Chengdu Baiyu Pharmaceutical Co Ltd Derivado de piperazina y uso del mismo en medicina.
CN117396485A (zh) * 2021-05-25 2024-01-12 轩竹生物科技股份有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
CN115677664A (zh) * 2021-07-23 2023-02-03 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
CN117279907A (zh) * 2021-08-06 2023-12-22 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
CN117377665A (zh) * 2021-08-16 2024-01-09 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
WO2023020457A1 (en) * 2021-08-17 2023-02-23 InventisBio Co., Ltd. Pyridazinone or pyridinone compounds, preparation methods and uses thereof
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116375688B (zh) * 2021-12-23 2025-04-11 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
CN116444497B (zh) * 2022-01-14 2025-06-24 如东凌达生物医药科技有限公司 一类哒嗪酮类化合物、制备及其应用
WO2023143236A1 (zh) * 2022-01-26 2023-08-03 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
CN116535395B (zh) * 2022-01-26 2024-07-09 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
AU2022451580B2 (en) * 2022-04-01 2024-11-07 Novostar Pharmaceuticals, Ltd. Parp7 inhibitor and use thereof
TW202346294A (zh) * 2022-04-21 2023-12-01 大陸商四川海思科製藥有限公司 吡嗪酮衍生物及其在醫藥上的應用
CN117586263A (zh) * 2022-08-09 2024-02-23 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
AU2023321458A1 (en) * 2022-08-09 2025-02-13 Kangbaida (Sichuan) Biotechnology Co., Ltd. Use of piperazine compound in combination with radiotherapy for treatment of tumor
KR20250044423A (ko) * 2022-08-09 2025-03-31 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. 피페라진 화합물과 pd-1 억제제 또는 pd-l1 억제제의 조성물 및 종양 치료에 있어서의 그의 용도
WO2024037558A1 (en) * 2022-08-17 2024-02-22 Jacobio Pharmaceuticals Co., Ltd. Solid forms of compound i or salts thereof
GB202213819D0 (en) 2022-09-22 2022-11-09 Duke Street Bio Ltd Pharmaceutical compound
CN115490671B (zh) * 2022-10-21 2024-05-14 水木未来(北京)科技有限公司 Parp7抑制剂及其制备方法
WO2024104354A1 (zh) * 2022-11-14 2024-05-23 成都百裕制药股份有限公司 一种取代的哌嗪衍生物的晶体及其制备方法
GB202217888D0 (en) 2022-11-29 2023-01-11 Duke Street Bio Ltd Pharmaceutical compound
WO2024146631A1 (zh) * 2023-01-06 2024-07-11 齐鲁制药有限公司 一种parp7抑制剂的制备方法
WO2024149234A1 (en) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Parp7 inhibitors and uses thereof
CN120917010A (zh) * 2023-01-10 2025-11-07 嘉兴和剂药业有限公司 Parp7抑制剂及其用途
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
TW202508597A (zh) * 2023-08-17 2025-03-01 大陸商康百達（四川）生物醫藥科技有限公司 一種呱嗪衍生物的藥物製劑、其製備方法及其用途
WO2025045134A1 (zh) * 2023-08-29 2025-03-06 康百达（四川）生物医药科技有限公司 一种哌嗪衍生物的制备工艺及其中间体
WO2025087383A1 (zh) * 2023-10-26 2025-05-01 深圳众格生物科技有限公司 作为parp7抑制剂的化合物
TW202519233A (zh) * 2023-11-13 2025-05-16 大陸商康百達（四川）生物醫藥科技有限公司 一種parp7抑制劑聯合用藥的藥物組合及其治療腫瘤的用途
CN117342983B (zh) * 2023-12-05 2024-02-06 康羽生命科学技术(苏州)有限公司 过乙酰化GalNAc-L96合成方法
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957365B1 (en) 1997-09-05 2006-02-01 Matsushita Electric Industrial Co., Ltd. Fluorescence polarization method
US6794158B2 (en) 2001-04-09 2004-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
CN1980899B (zh) * 2004-06-30 2013-07-24 詹森药业有限公司 作为parp抑制剂的喹唑啉酮衍生物
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
WO2008013838A2 (en) 2006-07-25 2008-01-31 Cephalon, Inc. Pyridizinone derivatives
MX2010005070A (es) * 2007-11-15 2010-05-24 Angeletti P Ist Richerche Bio Derivados de piridazinona como inhibidores de parp.
AU2009228943B2 (en) * 2008-03-27 2013-04-04 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
CN108752280A (zh) * 2009-08-17 2018-11-06 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
JP2016512239A (ja) * 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
WO2016116602A1 (en) * 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
AU2018334290A1 (en) * 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
TWI877697B (zh) 2018-04-30 2025-03-21 美商律幫治療股份有限公司 作為parp7抑制劑的嗒酮
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
US11691969B2 (en) 2019-10-30 2023-07-04 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibtors
US20240190844A1 (en) 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors

Also Published As

Publication number Publication date
HRP20230458T1 (hr) 2023-07-21
MX2020011465A (es) 2020-12-07
JP7518049B2 (ja) 2024-07-17
LT3788040T (lt) 2023-06-26
ZA202006549B (en) 2025-06-25
CA3098585A1 (en) 2019-11-07
SMT202300172T1 (it) 2023-09-06
IL308983A (en) 2024-01-01
IL278116B1 (en) 2023-12-01
AU2019262927B2 (en) 2023-11-02
ES2949538T3 (es) 2023-09-29
ECSP20069404A (es) 2021-01-29
IL308983B1 (en) 2025-06-01
CN112424188B (zh) 2025-06-27
SG11202010183XA (en) 2020-11-27
MD3788040T2 (ro) 2023-10-31
US10870641B2 (en) 2020-12-22
AU2024200566A1 (en) 2024-02-15
JP2021523104A (ja) 2021-09-02
EP4234551A3 (en) 2023-10-11
HUE062096T2 (hu) 2023-09-28
CY1126132T1 (el) 2023-11-15
FI3788040T3 (fi) 2023-06-13
CR20200518A (es) 2021-03-22
DK3788040T3 (da) 2023-05-08
BR112020022006A2 (pt) 2021-01-26
CN120987912A (zh) 2025-11-21
TWI811353B (zh) 2023-08-11
WO2019212937A1 (en) 2019-11-07
EP3788040B1 (en) 2023-04-12
KR20210014108A (ko) 2021-02-08
IL308983B2 (en) 2025-10-01
US20210024502A1 (en) 2021-01-28
TW202344505A (zh) 2023-11-16
TW202014416A (zh) 2020-04-16
MA52486B1 (fr) 2023-04-28
EA202092590A1 (ru) 2021-04-08
CN112424188A (zh) 2021-02-26
US11566020B1 (en) 2023-01-31
CL2020002821A1 (es) 2021-02-19
IL278116A (en) 2020-11-30
MA52486A (fr) 2021-03-10
IL278116B2 (en) 2024-04-01
JP6942896B2 (ja) 2021-09-29
US20200123134A1 (en) 2020-04-23
PH12020551760A1 (en) 2021-06-28
RS64283B1 (sr) 2023-07-31
AU2019262927A1 (en) 2020-11-12
AR121419A1 (es) 2022-06-08
TWI877697B (zh) 2025-03-21
US20250034120A1 (en) 2025-01-30
MX2023005804A (es) 2023-05-29
CO2020013599A2 (es) 2020-12-21
EP3788040A1 (en) 2021-03-10
SI3788040T1 (sl) 2023-07-31
PT3788040T (pt) 2023-07-12
US20190330194A1 (en) 2019-10-31
US10550105B2 (en) 2020-02-04
EP4234551A2 (en) 2023-08-30
KR102862474B1 (ko) 2025-09-24
US11014913B2 (en) 2021-05-25
US20230192664A1 (en) 2023-06-22
PE20211382A1 (es) 2021-07-27
JP2022017221A (ja) 2022-01-25

Similar Documents

Publication Publication Date Title
PL3788040T3 (pl) Pirydazynony jako inhibitory parp7
FIC20253006I1 (fi) Linvoseltamabi
EP3776673A4 (en) HIGH PERFORMANCE MICRO-LED
EP3846674C0 (en) VAGINAL SPECULUM
DK3810602T3 (da) Forbindelser
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
EP3849534A4 (en) COMBINATION THERAPIES
EP3828174A4 (en) Pyridazinone derivative
DK4177504T3 (da) Forbindelse
EP3781060A4 (en) CRYOPROBE
EP3784463A4 (en) Fluorosulfones
EP3872558A4 (en) OPTICAL ISOLATOR
EP3805381A4 (en) Phytase mutant
EP3876776C0 (en) CONNECTOR
EP3810860C0 (en) COUPLER
PL3999494T3 (pl) Podstawione pirydazynony jako herbicydy
EP3813204A4 (en) Connector device using lid member, and lid member
EP3885347A4 (en) DIHYDROPYRROLOPYRAZOLE DERIVATIVE
DK3810633T3 (da) Forbindelser
EP3761831A4 (en) FURNITURE SYSTEM
EP3721129A4 (en) CRYOSPHERE
EP3878374A4 (en) Occlusion device
EP3844177A4 (en) COMBINATION THERAPIES
EP3805997A4 (en) Lipid nanotablet
EP3770162A4 (en) DIHYDROCHROME DERIVATIVE